Recurring Consumables And ServicesReproCELL’s core revenue mix centers on consumables, reagents and fee-for-service work tied to customers’ R&D programs. That creates recurring, usage-linked demand and customer stickiness in academia and pharma, supporting stable revenue streams over months and reducing churn risk.

Very Low Debt / Strong Balance SheetA near-zero debt load gives durable financial flexibility: lowers solvency risk, preserves capacity to fund R&D, working capital or strategic investments without reliance on costly external financing, and supports resilience through biotech sector cycles over the next several months.

Improving Margins And Net Income InflectionGross margin expansion to ~55% and a return to net profitability indicate improving unit economics and pricing or mix gains. If sustained, higher gross margins provide the structural opportunity to absorb fixed costs and drive durable path to operating profitability over 2–6 months.

Bears Say

Weak Cash Generation / Negative FCFDespite accounting profits, FCF remains negative and operating cash flow is only marginally positive. This persistent cash shortfall constrains reinvestment, forces dependence on financing or equity, and raises execution risk for expansion or R&D spending in the medium term.

Operating Profitability Not Yet AchievedThe company has not converted improved gross margins into operating profit; core cost structure still produces an EBIT loss. This means earnings gains may be fragile and the firm remains vulnerable if revenue momentum slows before fixed costs are absorbed.

Low Returns On Shareholder CapitalROE near 1% signals weak capital efficiency and limited returns for shareholders following the recovery. Coupled with uneven historical revenue growth, this raises questions about the sustainability of value creation absent clearer, repeatable profit conversion.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥112.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥14.03B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is May 20, 2026 which is in 90 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on Feb 12, 2026. The company reported ¥0.29 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.29.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 94,802,895 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of ¥0.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.829%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.